Trials / Completed
CompletedNCT02440893
Understanding the Effect of Metformin on Corus CAD (or ASGES)
Understanding the Effect of Metformin on Corus CAD (MET Study)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 37 (actual)
- Sponsor
- CardioDx · Industry
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
The study goal was to understand the effect of Metformin on Age/Sex/Gene Expression Score (ASGES) or Corus CAD (henceforth "Corus") in pre-diabetic patients who are medication naive. This study provided data to determine if the Corus CAD (ASGES) signature was different in pre-diabetic patients when metformin was newly prescribed and taken.
Detailed description
The study goal was to understand the effect of Metformin on Age/Sex/Gene Expression Score (ASGES) or Corus CAD in pre-diabetic patients who are medication naive. This study provided data to determine if the Corus CAD (ASGES) signature was different in pre-diabetic patients when metformin was newly prescribed and taken. The primary aim of this study was to evaluate whether metformin used in pre-diabetic patients to prevent progression to type II diabetes had a significant effect on the gene expression levels measured in Corus. This was a prospective study. Subjects were enrolled from participating sites as applicable inclusion/exclusion criteria were met. The study aimed to enroll approximately fifty (50) patients.
Conditions
- Coronary Artery Disease
- Angina Pectoris
- Chest Pain
- Cardiovascular Diseases
- Coronary Heart Disease
- CAD
- CVD
- CHD
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Corus CAD (ASGES) |
Timeline
- Start date
- 2013-09-01
- Primary completion
- 2014-06-01
- Completion
- 2014-06-01
- First posted
- 2015-05-12
- Last updated
- 2019-01-31
Source: ClinicalTrials.gov record NCT02440893. Inclusion in this directory is not an endorsement.